Small Molecules from AI/ML-Focused Companies Entering the Clinic (Part II)

Despite significant investment over the past decade, only a handful of companies are now bringing clinical candidates discovered with the assistance of AI/ML forward. Though there’s a looseness to what should count as an “AI-discovered drug,” here we highlight internally-generated drug programs from companies focused on leveraging AI/ML in drug discovery, who have explicitly stated that AI/ML methods were involved in the discovery process. These include but are not limited to:

  • A SHP2 inhibitor discovered using molecular dynamics simulations of proteins
  • A CNS-penetrant HDAC inhibitor and allosteric MEK inhibitor in nontraditional indications
  • A pan-Trk inhibitor discovered using literature data-mining to support target ID

For a review of the history of AI/ML in drug discovery and more resources on the topic, check out part I, and for preclinical small molecule AI/ML companies, check out part III of this series. 

request a trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.

Interested in learning more? Submit this form to request a trial.

already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.


Join Subscribers from

…and hundreds more!